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Abstract
The rate of psychosis has drastically increased in recent years and the number of prescrip-
tions for psychiatric medications has made an even bigger jump. With the worrisome 
side effects of the medications, which can pose serious health risks and make medica-
tion compliance difficult, coupled with the prohibitive cost for many patients, there is an 
obvious need for alternative solutions. This review presents the ambit of phytotherapy 
in psychotic care. Interestingly, the review revealed that, plant-based medicines are rich 
in phytonutrients of antipsychotic importance and may be effective as stand-alone treat-
ments or supplementary to conventional interventions. Despite the emerging interest in 
phytotherapy for mental disorders, the majority of the formulations are yet to be clinically 
certified. However, simply disregarding them for this reason might be consequential and 
as such, for better and improved mental health, research into phytotherapeutic care for 
psychosis must remain to be continuously explored as a promising niche.
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1. Introduction
Feelings and perceptions like paranoia/hearing voices may be highly discomforting, worry-
ing, and necessitate people to seek definitive aid. Generally, help have been offered medi-
cally, and mental illnesses or psychosis have always been diagnosed for such feelings. Many 
individuals always assume that psychosis occur in the manner as other ailments exist and 
may be accurately revealed by medical tests in the same way. However, this is not always the 
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case and several theories are in place to significantly understand the causatives of mental dis-
orders. The notion that psychosis is a typical symptom of illnesses, possibly caused by some 
chemical imbalance or infiltrations in the brain, is just one of these theories [1]. While the rate 
of psychosis has drastically increased in recent years, the number of prescriptions for psy-
chiatric medications has made an even bigger jump [2, 3]. For instance, in the United States, 
the prescription and use of antidepressant drugs has increased by almost 400% between 1998 
and 2008 [4]. With the worrisome side effects of the medications, which can pose serious 
health risks and make medication compliance difficult, coupled with the prohibitive cost for 
many patients, there is an obvious need for alternative solutions. Interestingly, in addition 
to medical and clinical care for psychosis, the significance of phytotherapy has also become 
well established over the past decade. For instance, phytotherapeutic formulations such as St 
John’s Wort and Kava have potentiated remarkable clinical evidence [5]. Also, the beneficial 
effects of peppermint aroma from plants on memory and alertness have offered new oppor-
tunities for research regarding cognitive decline [6]. Such formulations are direct efforts of 
the plant-based remedies that have been used by indigenous cultures for thousands of years.
Although, attempts have been previously made on the review of the significance of traditional 
systems of medicines in the management of mental illnesses [5, 7–11], a comprehensive review 
on the ambit of herbal remedies and the mechanism of actions of the anti-psychotic bioactive 
principles is still lacking till date. It is on this background, that, this review was conducted to 
identify the major psychotic disorders, the broad scope of phytotherapy in psychotic care and 
the mechanisms of action of anti-psychotic phytonutrients.
2. Major psychotic disorders and classifications
Psychotic disorder forms a diverse group of illness that are serious and often treatable [12]. 
Psychotic disorders affect the way a person may act or feel (loss of motivation, delusion, 
social withdrawal from others, depression, intense elation, ‘uncontrollable laughter or cry-
ing’, altered emotions), thinking (confused or disjointed thoughts, superficially-irrelevant 
thinking, unconsolidated connections between ideas, and incoherence), auditory and visual 
hallucination [13]. These itemized features make it difficult for the affected individuals to 
distinguish between what is real and not real. On the other hand, psychosis encompasses 
conditions that influence the mind where contact with reality has been lost [14].
According to the American Psychiatric Association [15], psychotic disorders can be classi-
fied into four basic groups including; non-affective psychotic disorder (e.g. schizophrenia, 
schizoaffective, schizophreniform, delusional, brief psychotic, shared psychotic, and psy-
chotic disorder NOS), affective psychotic disorder (e.g. bipolar I and II disorder with psy-
chotic features and major depressive disorder with psychotic feature), substance-induced 
psychotic disorder (e.g. alcohol-induced psychotic disorder and other substance-induced), 
and psychotic disorder to general medical condition [16, 17].
Schizophrenia is one of the most common and severe psychotic disorders. It is a cluster of 
disorders characterized by fundamental disturbances of thinking, perception and emotions. 
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The onset of schizophrenia is often in young adulthood, and for those affected, the disorder 
often causes many years of intense suffering [12]. The course, sign and symptoms in affected 
individual are highly inconsistent, but for a smaller ratio, the disorder causes lifelong disabili-
ties with deterioration in functional capacity [18]. However, an average of 1 in every 7 patients 
with schizophrenia have been able to recover from the ailment despite the improvement in 
available treatment options in the recent years [19]. Schizophreniform disorder is basically 
identical with schizophrenia except that the ailment period is at least 1 month, but full recov-
ery in 6 months is required. Another difference is that decline in functioning is not required 
in diagnostic criteria of schizophreniform disorder, while decline in social and occupational 
function is one criteria of schizophrenia. The diagnosis is often provisional and diagnosis may 
be changed to schizophrenia, should symptoms remain longer than 24 weeks [20]. In schizoaf-
fective disorder on the other hand, the full criteria of both the active phase of schizophrenia 
and a mood episode should be met. In the same illness period, a 14-day delusional or halluci-
national feeling without obvious mood symptoms may be evident. Symptoms meeting criteria 
for a mood episode should be present for the duration of the disorder [21]. The delusional 
disorder is often characterized by non-bizarre delusions and mostly last for almost 4 weeks. 
However, with the exception of the presence of tactile and olfactory hallucinations, other 
active-phase signs of schizophrenia should not be present, particularly if they are delusional-
related. Besides the delusional impacts, normal behavior is always observed and functioning 
is not markedly impaired [15]. Unlike others, the brief psychotic occurrence is accompanied by 
sudden onset of psychotic symptoms (disorganized speech, delusions, catatonic behavior, hal-
lucinations,) which persist for at least 24 hours but usually not exceeding 4 weeks. After this, 
a full remission and return to an optimal level of functioning is normally achieved [22, 23]. 
Furthermore, a variant of the non-affective psychotic disorders, the shared psychotic ailment, 
occurs rarely and is normally characterized by delusional experience in one individual when 
in a close relationship with an established delusional person [24]. Also, with the psychotic dis-
order NOS, the symptoms of psychosis are evident, but a specific diagnosis of any psychotic 
disorder cannot be made. There may be inadequate information to make a specific diagnosis, 
the information is contradictory, or symptoms fail to fulfill full criteria for a specific psychotic 
disorder. According to Arciniegas [17], diagnosis may be assigned for example if; a postpar-
tum psychosis fails to meet criteria for a specific psychotic ailment, symptoms of psychosis 
have existed not beyond 4 weeks but yet to be remitted, occurrence of persistent auditory 
hallucinations void of any other psychotic feature, existence of persistent non-bizarre delu-
sions with episodes of overlapping mood, evidence of uncertainty as to whether symptoms of 
psychosis are primary or substance use related or of general medical issues [12].
Unlike the non-affective disorders, the bipolar I disorder is an affective type of psychosis, 
characterized with manic or mixed episodes, usually accompanied with major episodes of 
depression. Symptoms of psychosis, which have to be hallucinations/delusions, can occur 
during manic, mixed and severe depressive episodes [25, 26] Typical mood-congruent psy-
chotic symptoms during manic episodes include grandiosity and persecutory delusions 
linked to some special features of the person. Mood-incongruent psychotic symptoms include 
persecutory delusions without grandiose themes or delusions of thought insertion, thought 
broadcasting or being controlled [27]. The bipolar II disorder diagnosis means that person 
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has had at least one hypomanic, but no manic or mixed episodes, and one major depressive 
episode. Bipolar II disorder may also include psychotic symptoms during the severe depres-
sive episodes. Bipolar I disorder leads to hospitalizations, need for treatment, and decline in 
daily functioning more often compared with bipolar II disorder [28, 29]. Similarly, the major 
depressive disorder with psychotic features is diagnosed when the criteria for major depres-
sive disorder episode are met and delusions or hallucinations occur within the episode. 
Mood-congruent delusions or hallucinations are consistent with the depressive themes (delu-
sions of guilt, delusions of deserved punishment, nihilistic delusions etc.). Mood-incongruent 
delusions or hallucinations do not have any apparent relationship to depressive themes (per-
secutory delusions, delusions of thought insertion, delusions of control etc.) [30]. For the 
substance-induced psychotic disorders, the victim is characterized by prominent hallucina-
tions or delusions that are judged to be due to the direct physiological effects of a substance 
(drug of abuse, a medication, or a toxin exposure). Substance-induced psychotic disorders 
are distinguished from the substance-induced delirium (clear consciousness), from substance 
intoxication or withdrawal with perceptual disturbances (more persistent, clinically relevant 
symptoms, and the individual is void of insight) and from primary psychotic disorders [31]. 
The onset of substance use typically precedes the onset of psychotic symptoms, and the symp-
toms should disappear within 1 month after the substance use has ceased. Psychotic symp-
toms may occur during withdrawal or intoxication of these substances: cannabis, inhalants, 
hypnotics, hallucinogens, amphetamine, opioids, cocaine, alcohol, anxiolytics, phencyclidine 
and sedatives [32]. Some medications (e.g. antiparkinsonian medications, corticosteroids, 
anticholinergic agents, antimalarial medications and chemotherapeutic agents) can also 
trigger symptoms of psychosis. The clinical picture of psychosis varies depending on the 
substance [12]. For the one resulting from a general medical condition, the victim feels hal-
lucinated or delusioned. These symptoms can be judged to result from the direct physiologi-
cal impacts of a general medical condition, and they are not explained by any other mental 
disorder [33]. Clear temporal association should be found between the general medical issue 
and the onset of psychotic disturbance. Additionally, there must be literature evidence on the 
particular medical condition causing psychotic symptoms [34]. Examples of general medical 
conditions that can cause psychotic symptoms include temporal lobe epilepsy, brain lesions 
and tumors, central nervous system infections and any severe medical condition requiring 
treatment in intensive care unit [34, 35]. Delirium is a condition characterized by disturbance 
of consciousness and cognition which may have psychotic symptoms as an associated feature 
[36, 37]. The etiology of delirium varies, including substance-induced delirium and delirium 
due to underlying general medical issues. Irrespective of the cause, associated challenges 
emanate within the shortest time possible and usually not consistent during the course of the 
day [37–39].
3. Conventional treatment and management options
Many of the drugs that have been introduced for the treatment of psychotic disorders are 
known to interfere with the normal physiological actions of several of the brain neurotrans-
mitters and their receptors. The major brain neurotransmitters that have been implicated in 
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psychiatric disorders are: neuropeptides, epinephrine, norepinephrine, dopamine, acetylcho-
linesterase, 5-hydroxytryptamine, and Gamma-aminobutyric acid (GABA). In the hospital, 
many psychotic patients that are not confined to the bed and medication may be given and/
or administered at a central point rather than having a ‘drug round’. In psychiatric units, 
patient’s compliance may be a problem and it is often necessary to ensure that drug is taken 
[40, 41]. Occasionally, a patients’ paranoia may extend to the drugs they are given. They may 
think the staff members attending to them are trying to poison them [42].
Traditionally, antipsychotic drugs are classified as typical (classical) or atypical. The typi-
cal antipsychotic drugs are generally those that have been use for many years and common 
examples include; chlorpromazine, flupentixol, fluphenazine, haloperidol, and thioridazine 
[43]. The atypical antipsychotic drugs on the other hand, are more recent additions to the rep-
ertoire of drugs available. These drugs (e.g. amisulpride, clozapine, olanzapine, quetiapine, 
risperidone, zotepine) produce fewer adverse effects (e.g. tremor) on the motor system and 
may also help patients who do not respond to typical antipsychotic drugs [44].
4. Mechanism of action of antipsychotic drugs
Almost all antipsychotic drugs have many different pharmacological actions that it is very 
difficult to relate any one action to a therapeutic effect [45, 46]. Effective antipsychotic drugs 
share the ability to inhibit the physiological actions of dopamine D
2
 receptors in the brain [47]. 
Collectively, the drugs are quite useful in controlling the states of agitation observed/found 
in acute schizophrenia, mania and some other forms of delirium and in paranoia. Their exact 
mode of action in these conditions remains unknown but most of them block the action of 
dopamine on D
2
 receptors in the mesolimbic system of the brain and this seems crucial to their 
sedative and antipsychotic properties [48]. These drugs also inhibit the action of dopamine on 
chemoreceptor trigger zone of the brain and are thus antiemetic. Furthermore, drugs such as 
haloperidol prevent the action of the dopaminergic nerves that run from the substantia nigra 
to the corpus striatum. Disruption of physiological action of this system causes Parkinsonism 
and these drugs may cause various disorders of movement and posture [49].
5. Phytotherapy and the conventional therapies for psychosis
5.1. Conventional therapy
Contrary to phytotherapy that involves the use of medicinal plants, conventional therapy for 
psychosis is majorly by the use of medications. Others include cognitive therapy treatment, 
counseling, family or support group, the use of mood stabilizers etc. Cognitive therapy cen-
ters on identifying different patterns of thought (perception about situation) that brings about 
undesirable action or feelings. In some countries of the world particularly United Kingdom and 
United States, this kind of therapy is embraced (sometimes in combination with medications) as 
the most effective way of treating psychosis or psychosis-related disorder such as schizophrenia, 
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depression and or substance abuse. Additionally, family or support group form of psychosis 
therapy deals with the informal measure of treatment by a way of caring or providing support 
to people or family members suffering from the menace geared towards knowing how they fare 
on the various treatment or medications being exposed to and perhaps discussion on whether 
there is need for a change if medication is presenting havoc than alleviating the situation.
5.2. Medications as a form of therapy for psychosis
The discovery of chlorpromazine in the mid-1900s (1953) for the treatment of psychosis or related 
ailments led to the emergence of other conventional or typical antipsychotics such as perphen-
azine (marketed in 1957), trifluoperazine (1958), fluphenazine (1960), haloperidol (1966), thiothix-
ene (1968), loxapine (1978), flupentixol (1983) usually referred as the first line or first generation 
antipsychotics [45]. These traditional agents aside exhibiting different level of potencies such as 
low (e.g. chlorpromazine), intermediate (perphenazine), high (haloperidol) are embraced and 
adopted for short or long-term use against acute or chronic psychotic disorders (schizophre-
nia, schizoaffective and or delusional disorders, psychotic-depressive ailments, dementia etc.). 
Antipsychotics or neuroleptics (derived from the combination of neuron and ‘lepsis’ to mean 
‘take hold of nervous system’) ordinarily acts by blocking the Dopamine D
2
 receptors (protein) 
domicile in the limbic system and striatum, thus, producing adverse effects such as the develop-
ment of extrapyramidal side effects (EPSs), hyperprolactemia (elevated level of prolactin in the 
blood), neuroleptic malignant with Tardive dyskinesia, sexual dysfunction, restlessness, stiffness 
and shaking of the joints etc. among common names or features of these effects [50, 51].Moreover, 
the coming of the newer or modern or second generation antipsychotic drugs (Table 1) oth-
erwise referred to as atypical antipsychotics have in a way in recent times in clinical medicine 
replaced the use of first generation (FG) counterpart owing to their ability to lower some of the 
side effects known with FG. They exert these actions by proffering less affinity for D
2
 receptor, 
Antipsychotics Brand name Year of first market
Clozapine Clozaril 1991
Olanzapine Zyprexa 1996
Quetiapine Seroquel 1998
Risperidone Risperdal 2004
Ziprasidone Zeldox 2009
Aripiprazole Abilify 2013
Asenapine Saphris 2009
Iloperidone* Zomaril 2009
Blonanserin Lonasen 2009
Lurasidone* Latuda 2010
*Not yet approved by Food, Drug and Administration (FDA, US).
Table 1. Modern antipsychotics.
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higher affinities for other neuroreceptors such as serotonin (e.g. 5-HT
1A
, 5-HT
2A
 etc.) and nor-
epinephrine (α1, α2 subtypes) as well as regulate glutamate receptor-mediated functions and 
behaviors among others [51, 52]. However, it is interesting to note that with issues relating to 
pharmacological effect, efficacy, safety, tolerability, cost effectiveness and adverse effects, it is 
important to weigh the pros and cons between both sides in terms of the above enumerated 
factors. In fact, there are reports that these newer generation drugs are more expensive, although 
the benefits they rendered outweighs the financial implications and are of less consequence as 
highlighted by clinicians and policy makers [51]. Similarly, despite revelations of side effects 
such as weight gain attributed to some modern class of antipsychotics such as Clozapine and 
Olanzapine but evidence as to why this is so is still unclear. Above all, in a review by Gardner and 
others [45] at comparing the superiority between typical and atypical antipsychotics taking into 
consideration above factors, they affirm the supremacy of the atypical antipsychotics over the old 
ones as evidenced in a number of cited reports (though accompanied with limitations) but still, 
generated huge number of prescriptions and acceptance globally [53–55].
5.3. Phytotherapy in psychotic care
Herbal medicine or phytotherapy according to World Health Organization (WHO) means 
herbal (medicinal plant) product containing the active components of plant parts or materi-
als or both combined. In recent times, the use of medicinal plants in complementary and 
alternative medicine has continued to receive wider publicity in many quarters of the world. 
In fact 80% of the entire global population makes use of one form of traditional medicine 
in the prevention, diagnosis and treatment of numerous diseases facing them while also 
being incorporated within their national healthcare system. Psychosis, a mental condition 
resulting in the ability of an individual to witness distorted or total loss of contact with real-
ity is considered among the neuropsychiatric disorders according to WHO with 13–49% of 
individual worldwide being affected by them at a particular stage within their life time [13]. 
Many medicinal plants and orthodox medicines are embraced and used in the management 
of this derangement [13, 45, 56], despite the numerous adverse effects including but not lim-
ited to restlessness, sexual dysfunction, extrapyramidal (EPSs) such as tardive dyskinesia 
(persistent tongue, mouth and jaw movement), malignant syndrome etc. attributed to these 
chemical moieties [51]. Interestingly, it is worthy of mention that out of several medicinal 
plants with reported antipsychotic effect [13, 11], very few, such as Lemon balm (Melissa offi-
cinalis), Yokukansan (TJ-54), Ginkgo (Ginkgo biloba), Valerian (Valeriana officinalis), St John’s 
wort (Hypericum perforatum), Kava-kava (Piper methysticum) have been developed as agents 
with reported use for phytotherapy while being functioning as antidote against prominent 
psychiatric ailments (depressive, somatic, psychotic, anxiety, sleep) [5, 57] with the latter 
four agents among the first 10 best-selling herbal formulations in the US [13] and Africa in 
the management of neurological diseases [58], although, there are reports of agent like St 
John’s wort inducing psychosis [59, 60]. In fact, despite their wide usage and preference over 
conventional antipsychotic drugs with varying adverse effects [61], psychiatric patients have 
continued to adopt herbal therapy for the management of psychosis [11]. The respective list of 
selected medicinal plants commonly used in psychotic care and the most prominently impli-
cated phytonutrients of antipsychotic significance are presented in Tables 2 and 3.
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Family Species Parts Folkloric 
usage
Scientific 
validation
Toxicity Phytonutrients
Alliaceae Agapanthus 
campanulatus 
F.M. Leighton
Root Decoction 
of the root is 
taken orally 
[62]
Extract exhibited 
serotonin, 
noradrenalin, 
and dopamine 
transporter 
inhibitors  
[63, 64].
No 
record
Flavonoid [64]
Amaryllidaceae Boophane disticha 
(L.f.) herb
Leaves 
and 
bulbs
Decoctions 
of bulb 
scales given 
to sedate 
violent, 
psychotic 
patents [65]
Affinity to 
the serotonin 
transporter 
protein [66]; 
It also inhibited 
serotonin, 
noradrenalin 
and dopamine 
transporters  
[64]
No 
record
Alkaloids (buphanidrine 
and buphanamine) [64]
Anacardiaceae Spondias mombin 
L.
Leaves Leaves 
extract 
is used 
traditionally 
[67]
The aqueous 
extract prolonged 
the sleeping time 
and decreased 
the stereotyped 
behavior [67]
Non-
toxic 
[67]
Tannins, anthraquinones, 
flavonoids, glycosides. 
Phenols, saponins, 
phlobatannins and 
alkaloids [67]
Apocynaceae Rauvolfia 
vomitoria Afzel.
Root The root 
is ground 
into powder 
and taken 
with pap or 
decoctions 
orally 
taken [68]
Decreased 
locomotor 
behavior [69]
Non-
toxic 
[70]
Beta-carboline alkaloid, 
alstonine [69]
Apocynaceae Rauvolfia 
tetraphylla L.
Leaves No record Significant affinity 
for 5-HT2A and 
DA-D2 receptors 
[71]
Non-
toxic 
[71]
11demethoxyreserpiline 
(3) and 
10-demethoxyreserpiline 
(4), α-yohimbine (5) and 
reserpiline [71]
Asclepiadaceae Gomphocarpus 
physocarpus 
E. Mey
Leaves Powdered 
leaf is used 
to sedate 
psychotic 
patient [65]
The extract 
inhibited 
monoamine 
oxidase [72]
No 
record
Carbohydrates, cardiac 
glycosides, steroids/
terpenoids, alkaloids and 
phenols [73]
Asclepiadaceae Xysmalobium 
undulatum (L.) 
Aiton.f.
Root Roots 
administered 
[74]
Extracts exhibited 
SSRI activity [64]
No 
toxicity 
[75]
Flavonoid (xysmalorin 
and uzarin) [64]
Euphorbiaceae Securinega virosa 
(Roxb ex. Willd) 
Baill.
Leaves 
and 
root
Decoction 
of the leaves 
and roots 
[76]
The extract 
exhibited 
significant effect 
on D1 receptor 
by inhibiting 
grooming 
and climbing 
behaviors in 
rats [76].
Non- 
toxic 
[77]
Alkaloids, saponin, 
flavonoid, and tannin [76]
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Family Species Parts Folkloric 
usage
Scientific 
validation
Toxicity Phytonutrients
Fabaceae Afzelia Africana 
Smith
Stem 
bark
Fresh 
stembark of 
Lophira alata 
and A. africana 
are powdered 
together. The 
powder is 
then infused 
in water for 
2 h and given 
to the patient 
to drink and 
bath [78]
The extract 
reduced the 
locomotive 
activity, rearing 
and sniffing in 
rats [78]
Non 
-toxic 
[79]
Alkaloids, tannins, 
saponins, flavonoids, 
triterpenoid, phytosterols 
and glycosides [79]
Fabaceae Amblygonocarpus 
andongensis
Stem 
bark
Aqueous 
extract of the 
stem bark is 
taken orally 
[80]
The extract 
reduced the 
psychotic 
behavior 
characterized 
by anorexia and 
agitation in rats 
[81]
Mildly 
toxic 
and has 
reducing 
effects on 
weight 
[80]
No record
Fabaceae Arachis 
hypogaea L
Leaves 
and 
stem
Aqueous 
extract of the 
leaves taken 
orally [82]
It has sedative 
effect [83]
No 
records
Linalool [83]
Fabaceae Lonchocarpus 
cyanescens 
(Schumach and 
Thonn.) Benth.
Leaves It is used in 
combination 
with another 
recipe of 
plant origin 
[84]
The extract 
inhibited 
stereotype 
behavior and 
spontaneous 
motor activity [84]
No 
records
Alkaloids, 
anthraquinones, cardiac 
glycosides, cyanogenetic 
glycosides, flavonoids, 
saponins, steroids and 
tannins [84]
Lamiaceae Ocimum 
sanctum L.
Leaves Extract from 
the leaves is 
taken orally 
[85]
Attenuation 
of locomotory 
activity and 
dopamine levels 
[85]
Non-
toxic 
[86]
Eugenol, cardinene, 
cubenol, borneol, 
linolenic acid, oleic acid, 
palmitric acid, steric acid, 
vallinin, vicenin, vitexin, 
vllinin acid, orientin, 
circineol, gallic acid, 
vitamin A, vitamin C, 
phosphorus and iron [87]
Lamiaceae Mentha 
aquatica L.
Leaves Mixed with 
leaves of 
Tagetes minuta 
L. burned and 
the smoke is 
inhaled [88]
Leaf extracts 
exhibited SSRI 
activity and 
MAO-B inhibitory 
activity [63, 89]
No 
record
Flavones and flavanone 
derivatives [90]
Liliaceae Allium cepa Linn Bulb Paste [91]. Onion paste 
inhibited 
dopaminergic 
neurotransmission 
and possibly 
blocks 
dopamine D2 
receptor [91]
Non-
toxic 
[92]
Phenolic acid, flavonoids, 
anthocyanin, sterols, 
vitamins, pectin and 
peptides [91].
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Family Species Parts Folkloric 
usage
Scientific 
validation
Toxicity Phytonutrients
Ochnaceae Lophira alata 
Banks ex. 
Gaertn.f.
Stem 
bark
Fresh 
stembark is 
powdered 
with Afzelia 
africana 
stembark. 
It is then 
infused in 
water for 2 h 
and given to 
the patient 
to drink and 
bath [78].
The extract 
reduced 
locomotive 
activity and 
rearing in rats [78]
Non-
toxic 
[79]
Alkaloids, tannins, 
saponins, flavonoids, 
triterpenoid, phytosterols 
and glycosides [79]
Piperaceae Piper guineense 
Schum & Thonn
Fruit No record Significant 
reduction on 
rearing, locomotor 
activity and dips 
in mice [93]
Non-
toxic 
[94]
β-Sesquiphellandrene, 
limonene, linalool [93]
Rutaceae Ruta graveolens 
L.
Leaves Decoction 
of the leaves 
and oil 
extract are 
used [95]
It exhibited MAO 
inhibitory activity 
[89]
No 
toxicity 
[96]
Furocoumarins, 
furoquinolines and 
acridone alkaloids [89].
Solanaceae Datura 
stramonium L.
Leaves 
and 
seeds
Information 
not provided 
[65, 97]
The seeds and 
leaves of D. 
stramonium are used 
to sedate psychotic 
patients [98]
Toxic 
[97]
Alkaloids, tannins, 
saponins and cardiac 
glycosides [97]
Table 2. Medicinal plants list of plant with antipsychotic potential, their ethnopharmacology, toxicity and mechanism 
of actions.
Active compound Mechanism of action References
Ursolic acid (terpene) Activation of dopamine D
1
 and D
2
 receptors [99]
Reserpiline(alkaloid) inhibition binding to DA-D2 and 5-HT2A receptors [71]
α-Yohimbine (alkaloid) inhibition binding to DA-D2 and 5-HT2A receptors [71]
Methylaplysinopsin (alkaloid) Inhibition of monoamine oxidase (MAO) and displacement 
serotonin from its receptors
[100]
Polygalasaponins (saponin) Affinity for dopamine and serotonin receptors [101]
Yuanzhi-1 (triterpenoid saponin) Uptake of inhibitor that block dopamine, norepinephrine and 
serotonin transporters
[102]
Geranial, neral and 6-methyl-5-hepten-
2-one, citronellal, geranyl-acetate, 
β-caryophyllene and β-caryophyllene-
oxide, and 1,8 cineole (terpene)
Nicotinic and muscarinic cholinergic receptor binding 
properties in human brain tissue, acetylcholinesterase inhibitory 
properties and inhibition of enzyme GABA transaminase, 
leading to increased GABA activity
[103, 104]
Tropane (alkaloid) Muscarinic acetylcholinesterase receptor antagonist [105]
Purine (alkaloid) Receptor interactions, specifically involving DA D1 receptor 
signaling
[106]
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Active compound Mechanism of action References
Isoquinoline (alkaloid) Opioid receptor binding [107]
Pyridine (alkaloid) Agonist nicotinic acetylcholinesterase receptor binding [108]
Physostigmine (alkaloid) Cholinesterase inhibitor and direct agonistic nicotinic 
acetylcholinesterase receptor binding
[109]
Pilocarpine (alkaloid) Muscarinic acetylcholinesterase receptor agonist [105]
Reserpine (alkaloid) Irreversible blockage of norepinephrine and dopamine [110]
β-Sesquiphellandrene (terpene) Inhibition of dopamine neurotransmission at D1/D2 receptors [93]
Buphanidrine and buphanamine 
(alkaloids)
Affinity to the serotonin transporter (SERT) protein [66]
Xysmalorin and uzarin (flavanoids) Affinity for SERT in the binding assay. [64]
Atropine (alkaloid) CNS depressants and competitively antagonize muscarinic 
cholinergic receptors.
[111]
Scopolamine (alkaloid) CNS depressants and competitively antagonize muscarinic 
cholinergic receptors.
[111]
Agathisflavone and amentoflavone 
(flavanoid)
Affinity for GABAA-benzodiazepine receptor [110]
Table 3. Psychoprotective bioactive metabolites.
Figure 1. A unified mechanism of actions of antipsychotic phytonutrients. MP, medicinal plants.
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Taken together, a unified mechanism of actions of the antipsychotic phytonutrients could be 
proposed as presented in Figure 1. This may be conceptualized to potentiate either (a) modu-
latory role on dopamine D
1
 and D
2
 receptors, (b) regulation of serotonin reuptake/transport-
ers, (c) inhibitory effect on the specific activity of monoamine oxidase, or (d) regulation of the 
specific activities of acetylcholinesterase and Gama-aminobutyric acid transaminase. Plants 
endowed with these metabolites (Figure 1) may unilaterally or synergistically be employed 
with other conventional antipsychotic therapies to achieve optimal results in alleviating the 
ill episodes of the different forms (depression, hallucination, schizophrenia, etc.) of psychosis 
related disorders.
6. Conclusion
Conclusively, considering the potential benefits of medicinal plants in antipsychotic care, 
it may be evidently suggested that, there is a need for an inclusive integrative approach 
to manage and treat psychosis. One of such strategies may be to embrace traditional 
systems of medicine with the use of medicinal plants. This is mainly due to the plants 
being endowed with antipsychotic phytonutrients and demonstrating significant results 
in the management of mental health disorders. However, embracing herbal formulations 
in combination with conventional pharmaceuticals may provide better outcome with a 
view to targeting different aspects of mental being alertness. Although this concept may 
be controversial, research into phytotherapeutic care for psychosis is a promising niche for 
further studies.
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